ArticleNature medicine2023
A H3K27M-targeted vaccine in adults with diffuse midline glioma.
Open access · hybridAbstract read
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
20.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 72 citations in OpenAlex.
- Adult Thalamic Diffuse Midline Glioma, H3 K27-Altered, WithJournal of medical cases · 2026Article
- Immunotherapy for Glioma: A compartmental framework for resistance and rational combination design.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Review
- Brain barriers at the crossroads of glioma immune surveillance and immunotherapy response.Nature reviews. Cancer · 2026Review
- IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.Nature cancer · 2026Article
- Immunotherapy for Diffuse Midline Glioma: From Preclinical Modeling to Clinical Translation.Cancers · 2026Review
- Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications.NPJ precision oncology · 2026Review
- Sequence-Anchored Shared Tumor-Specific Epitopes for Pre-Manufactured HLA-Matched mRNA Cancer Vaccine Libraries: A Pan-Cancer Framework.Biomolecules · 2026Article
- Harnessing the power of biomarkers for diffuse intrinsic pontine gliomas.Nature medicine · 2026Article
- Therapeutic efficacy of dendritic cell vaccination in a novel syngeneic mouse model of diffuse hemispheric glioma, H3 G34-mutant.Journal of neuro-oncology · 2026Article
- Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review).Oncology reports · 2026Review
- The promise of immunotherapy for central nervous system tumours.Nature reviews. Immunology · 2026Review
- Identification of molecularly targeted therapy-induced immunopeptidome in diffuse midline glioma (DMG).Neoplasia (New York, N.Y.) · 2026Article
- From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.Cellular and molecular neurobiology · 2026Review
- Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas.Journal of neuro-oncology · 2026Article
- Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions.Journal of neuro-oncology · 2026Review
- Emerging frontiers in glioma therapy: the evolving role of glioma vaccines.Frontiers in immunology · 2026Review
- Biomarkers for predicting and monitoring the efficacy of cancer vaccines.Frontiers in oncology · 2026Review
- Diffuse midline glioma, H3K27-altered, mimicking central neurocytoma on MRI: A case report.Radiology case reports · 2026Article
- Adaptive immunotherapeutic paradigms in diffuse midline glioma: integrating epigenetic reprogramming, neuron-glioma interactions, and tumor microenvironment modulation.Journal of neuro-oncology · 2025Review
- The great imitator: clinical, surgical, and molecular insights into diffuse midline gliomas, H3 K27-altered. Illustrative cases.Journal of neurosurgery. Case lessons · 2025Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
26 authors at 7 institutions in 1 country.
Niklas GrasslDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-7987-0444
Isabel PoschkeDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4387-5566
Katharina LindnerDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-2735-3266
Lukas BunseDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4490-7574
Iris MildenbergerDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tamara BoschertDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0009-0007-8957-5319
Kristine JähneDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Edward W GreenDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ingrid HülsmeyerDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Simone JüngerDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Tobias KesslerDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Abigail K SuwalaDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
Philipp EiseleDepartment of Neurology, Medical Faculty Mannheim, MCTN, Heidelberg University, Mannheim, Germany.
Michael O BreckwoldtDKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-9980-2390
Peter VajkoczyDepartment of Neurosurgery, Charité-Universitätsmedizin Berlin, Berlin, Germany.
Oliver M GrauerDepartment of Neurology with Institute of Translational Neurology, University of Münster, Münster, Germany.ORCID http://orcid.org/0000-0003-4279-4497
Ulrich HerrlingerDivision of Clinical Neurooncology, Department of Neurology, University Hospital Bonn, University of Bonn, Bonn, Germany.
Joerg-Christian TonnDepartment of Neurosurgery, University of Munich LMU, Munich, Germany.
Monika DenkInstitute of Cell Biology, Department of Immunology, University of Tübingen, Tübingen, Germany.
Felix SahmDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5441-1962
Martin BendszusDepartment of Neuroradiology, Heidelberg University Hospital, Heidelberg, Germany.
Andreas von DeimlingDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5863-540X
Frank WinklerDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany.
Wolfgang WickDepartment of Neurology, University Hospital Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-6171-634X
Michael Platten *DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. m.platten@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0002-4746-887X
Katharina Sahm *DKTK CCU Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. k.sahm@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0001-7694-0988
German Cancer Research Center · DEHeidelberg University · DECharité - Universitätsmedizin Berlin · DELMU Klinikum · DEUniversity of Bonn · DEUniversity of Münster · DEUniversity of Tübingen · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Substitution of lysine 27 to methionine in histone H3 (H3K27M) defines an aggressive subtype of diffuse glioma. Previous studies have shown that a H3K27M-specific long peptide vaccine (H3K27M-vac) induces mutation-specific immune responses that control H3K27M
Indexed as
Brain NeoplasmsGliomaVaccinesAdultAnimalsHistonesHumansMiceMutationHistonesVaccines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.